Tobira Therapeutics Inc. Announces Date Of 2015 Second Quarter Financial Results And Conference Call

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, will report financial results for the quarter ended June 30, 2015 after market close on Tuesday, August 11, 2015. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

Conference Call Information:
Domestic callers: 1 (855) 638-8858
International callers: +1 (707) 294-1299
Passcode: 91340309

Webcast information: Visit http://ir.tobiratherapeutics.com/.

A webcast replay will be available on the Tobira Web site for 30 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1 (855) 859-2056 for domestic callers, or +1 (404) 537-3406 for international callers, and entering reservation code 91340309.

About Tobira Therapeutics, Inc.
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and HIV. Learn more about Tobira at www.tobiratherapeutics.com.

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2015 Tobira Therapeutics, Inc. All Rights Reserved.

Tobira Investor & Media Contact:
Ian Clements, PhD
+1 (650) 351-5013
ir@tobiratherapeutics.com

Canale Communications Media Contact:
Pam Lord
+1 (619) 849-6003
pam@canalecomm.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tobira-therapeutics-announces-date-of-2015-second-quarter-financial-results-and-conference-call-300123611.html

SOURCE Tobira Therapeutics, Inc.